Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US

Applied Health Economics and Health Policy

Volumn 11, Issue 5, 2013, Pages 485-497

  Parthan, Anju ^a,e   Kruse, Morgan ^a   Yurgin, Nicole ^b   Huang, Joice ^b,d   Viswanathan, Hema N ^b   Taylor, Douglas ^a,c  

^a OPTUM   (United States)

^b AMGEN INC   (United States)

^c Ironwood Pharmaceuticals   (United States)

^d Roche Diagnostics Corporation   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; GENERIC DRUG; IBANDRONIC ACID; RISEDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; CELLULITIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SPINE FRACTURE; TREATMENT DURATION; UNITED STATES;

AGED; AGED, 80 AND OVER; ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG COSTS; ETIDRONIC ACID; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MARKOV CHAINS; OSTEOPOROSIS, POSTMENOPAUSAL; SWEDEN; THIOPHENES; UNITED STATES;

EID: 84886899107     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0047-8     Document Type: Article

References (56)

1. National Institutes of Health (NIH) Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95.
2. Kanis JA. WHO Technical Report 2007. University of Sheffield, UK.
3. Melton LJ III, Chrischilles EA, Cooper C, et al. Perspective: how many women have osteoporosis? J Bone Miner Res. 1992;7(9):1005-10.
4. US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Office of the Surgeon General; 2004.
5. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006;119(4 Suppl 1):S3-11.
6. Delmas PD, Rizzoli R, Cooper C, Reginster JY. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int. 2005;16:1-5.
7. Osterberg L, Blaschke T. Adherence to medication. NEJM. 2005;353:487-97.
8. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17:1645-52.
9. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. NEJM. 2009;361(8):756-65.
10. Freemantle N, Satram-Hoang S, Tang E-T, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317-26.
11. Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22:967-82.
12. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone. 2010;47(1):34-40.
13. Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics. 2011;29(10):895-911.
14. Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951-61.
15. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727-36.
16. Denosumab (Prolia) Prescribing Information, June 2010I.
17. National Institute for Health and Clinical Excellence (UK). Systematic reviews of clinical effectiveness prepared for the guideline 'Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk'. National Collaborating Centre for Nursing and Supportive Care, September 2008. http://www.nice.org.uk/guidance/index.jsp? action=download&o=42362.
18. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972-80.
19. Melton LJ III, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int. 1999;9(1):29-37.
20. Melton LJ III, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993;3:113-9.
21. Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7(2):221-7.
22. http://www.Mortality.org. US Life Tables 2007.
23. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004;15(2):108-12.
24. Poor G, Atkinson EJ, O'Fallon WM, et al. Determinants of reduced survival following hip fractures in men. Clin Orthop. 1995;319:260-5.
25. Kanis J, et al. Excess mortality after vertebral fracture. Sheffield: WHO Collaborating Centre for Metabolic Bone Diseases; 2002.
26. Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health. 1991;105(6):443-6.
27. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone. 2003;32(5):468-73.
28. Haentjens P, Magaziner J, Colon-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Int Med. 2010;152:380-90.
29. Peasgood T, Herrmann K, Kanis JA, et al. An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853-68.
30. Borgstrom F, Johnell O, Kanis JA, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmocoeconomics. 2004;22(17):1153-65.
31. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000;15(7):1384-92.
32. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2001;12(12):1042-9.
33. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum. 2001;44(11):2611-9.
34. Hall SE, Criddle RA, Comito TL, Prince RL. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int. 1999;9(6):508-15.
35. Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int. 2006;17(12):781-93.
36. Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26(4):391-400.
37. Marketscan Database Analysis. Data on file-Amgen 2010.
38. National Hospital Discharge Survey (NHDS) Data 2006 - National Center for Health Statistics: Centers for Disease Control and Prevention.
39. Bentler SE, Liu L, Obrizan M, et al. The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epi. 2009;170(10):1290-9.
40. Stevenson M, Davis S. Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, edifronate and teriparatide. 2006. http://www.nice.org.uk/page.aspx?0=370643. Accessed 12 May 2008.
41. Healthcare Costs & Utilization Project Database based on US Nationwide Inpatient Sample. http://hcupnet.ahrq.gov/.
42. Denosumab Clinical Study Report, Nov 2008.
43. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab. 2004;30(6):549-56.
44. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed in a managed care population. Bone. 2006;38(6):922-8.
45. Solomon D, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch inter Med. 2005;165(20):2414-9.
46. Kanis JA, Reginster JY, Kaufman JM, et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23(1):213-21.
47. Boonen S, McClung M, Minisola S, et al. 2009. Effect of denosumab on the incidence of hip, new vertebral and nonvertebral fractures over 3 years among postmenopausal women with higher fracture risk: a subgroup analysis from the FREEDOM study. J Bone Miner Res 24(Suppl 1). http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx?aid=da35831c-de93-4607-8b12-b7fcaf42f45d. Accessed March 23 2012.
48. Inderjeeth CA, Foo ACH, Lai MMY, et al. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone. 2009;44(5):744-51.
49. McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal ostoeoporosis. J Bone Miner Res. 2011. doi: 10.1002/jbmr.536.
50. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333-40.
51. Meadows ES, Klein R, Rousculp MD, et al. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health. 2007;7(6):1-9.
52. National Osteoporosis Foundation. Osteoporos Int. 1998; (Suppl 4)S7-S80.
53. Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;166:1209-17.
54. Physician's Fee and Coding Guide 2012. MAG Mutual Healthcare Solutions, 2011.
55. Drug Topics Red Book. Montvale: Thomson Healthcare; 2010.
56. AnalySource 2011. WAC Pricing, November 1, 2011.